VISEN Pharmaceuticals (VSNPF)

Market Cap	172.82M -64.9%
Revenue (ttm)	5.01M +3,950.1%
Net Income	-35.26M
EPS	-0.33
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.100
Previous Close	2.100
Day's Range	2.100 - 2.100
52-Week Range	2.100 - 2.100
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parath...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 102
• Stock Exchange: OTCMKTS
• Ticker Symbol: VSNPF

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error